Kineret adds RA structural damage indication
Executive Summary
Amgen Kineret (anakinra) indication expanded to include slowing the progression of structural damage in moderately to severely active rheumatoid arthritis following FDA approval Aug. 22. The intravenous drug was originally approved in 2001 for the signs and symptoms of RA...